ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Price & Overview
FRA:DUL • US02043Q1076
Current stock price
The current stock price of DUL.DE is 275.9 EUR. Today DUL.DE is up by 0.4%. In the past month the price decreased by -5.38%.
DUL.DE Key Statistics
- Market Cap
- 36.449B
- P/E
- 160.41
- Fwd P/E
- 47.32
- EPS (TTM)
- 1.72
- Dividend Yield
- N/A
DUL.DE Stock Performance
DUL.DE Stock Chart
DUL.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DUL.DE.
DUL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DUL.DE. Both the profitability and the financial health of DUL.DE get a neutral evaluation. Nothing too spectacular is happening here.
DUL.DE Earnings
On February 12, 2026 DUL.DE reported an EPS of 0.82 and a revenue of 1.10B. The company missed EPS expectations (-28.48% surprise) and missed revenue expectations (-8.27% surprise).
DUL.DE Forecast & Estimates
36 analysts have analysed DUL.DE and the average price target is 408.75 EUR. This implies a price increase of 48.15% is expected in the next year compared to the current price of 275.9.
For the next year, analysts expect an EPS growth of 238.33% and a revenue growth 47.06% for DUL.DE
DUL.DE Groups
Sector & Classification
DUL.DE Financial Highlights
Over the last trailing twelve months DUL.DE reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 191.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.45% | ||
| ROA | 6.32% | ||
| ROE | 39.76% | ||
| Debt/Equity | 3.14 |
DUL.DE Ownership
DUL.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 24.48 | 36.709B | ||
| 1AE | ARGENX SE | 24.39 | 36.66B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.419B | ||
| 2X1 | ABIVAX SA | N/A | 8.413B | ||
| ABVX | ABIVAX SA | N/A | 8.382B | ||
| GLPG | GALAPAGOS NV | N/A | 1.849B | ||
| GXE | GALAPAGOS NV | N/A | 1.849B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.073B | ||
| PHIL | PHILOGEN SPA | 18.41 | 672.52M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 872.06 | 455.276M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DUL.DE
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
IPO: 2004-05-28
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS US
Employees: 2500
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / DUL.DE FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the stock price of ALNYLAM PHARMACEUTICALS INC today?
The current stock price of DUL.DE is 275.9 EUR. The price increased by 0.4% in the last trading session.
Does DUL stock pay dividends?
DUL.DE does not pay a dividend.
How is the ChartMill rating for ALNYLAM PHARMACEUTICALS INC?
DUL.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is DUL.DE stock listed?
DUL.DE stock is listed on the Frankfurt Stock Exchange exchange.
Is ALNYLAM PHARMACEUTICALS INC (DUL.DE) expected to grow?
The Revenue of ALNYLAM PHARMACEUTICALS INC (DUL.DE) is expected to grow by 47.06% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns ALNYLAM PHARMACEUTICALS INC?
You can find the ownership structure of ALNYLAM PHARMACEUTICALS INC (DUL.DE) on the Ownership tab.